Vol 81, Supp. I (2023): Zeszyty Edukacyjne 1/2023
Opinie i stanowiska ekspertów
Published online: 2023-09-27
Komentarze zespołu ekspertów — kardiologów i onkologów do wytycznych Europejskiego Towarzystwa Kardiologicznego 2022 dotyczących kardioonkologii
DOI: 10.33963/v.kp.96832
Abstract
Dynamiczny rozwój różnych terapii onkologicznych skutkuje wzrostem odsetka wyleczeń, a nawet zaawansowany nowotwór można ustabilizować, co pozwala na poprawę przeżywalności przez miesiące lub lata, zwiększając tym samym populację pacjentów onkologicznych. W populacji chorych na nowotwory wśród różnych chorób współistniejących choroby układu sercowo-naczyniowego stanowią rosnący problem kliniczny o istotnym wpływie na przeżycie.
Co więcej, lista potencjalnie kardiotoksycznych leków przeciwnowotworowych stale się powiększa, dlatego nadzór nad układem sercowo-naczyniowym jest konieczny przed (unikając opóźnień w leczeniu raka), w trakcie, a nawet po skutecznej terapii przeciwnowotworowej. Dlatego też, aby rozwiązać złożone problemy związane z rakiem i chorobami układu krążenia, kardioonkologia rozwinęła się jako nowa dziedzina medycyny.
W niedawno opublikowanych wytycznych Europejskiego Towarzystwa Kardiologicznego 2022 dotyczących kardioonkologii przedstawiono zwięzły, ale bardzo jasny opis, który powinien ułatwić pracownikom służby zdrowia podejmowanie decyzji w ich praktyce. Zaprezentowane wytyczne zostały uzupełnione komentarzami zespołu polskich ekspertów — kardiologów i onkologów, co wydaje się wnosić dodatkowe praktyczne informacje.
Keywords: kardioonkologianowotwórtoksyczność sercowo-naczyniowa związana z leczeniem onkologicznymwytyczne ESC
References
- Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022; 43(41): 4229–4361.
- Anker MS, Sanz AP, Zamorano JL, et al. Advanced cancer is also a heart failure syndrome: a hypothesis. Eur J Heart Fail. 2021; 23(1): 140–144.
- Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–3337.
- Pudil R, Mueller C, Čelutkienė J, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020; 22(11): 1966–1983.
- Čelutkienė J, Pudil R, López-Fernández T, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020; 22(9): 1504–1524.
- Martín-Garcia A, López-Fernández T, Mitroi C, et al. Effectiveness of sacubitril-valsartan in cancer patients with heart failure. ESC Heart Fail. 2020; 7(2): 763–767.
- Szmit S, Grela-Wojewoda A, Talerczyk M, et al. Predictors of new-onset heart failure and overall survival in metastatic breast cancer patients treated with liposomal doxorubicin. Sci Rep. 2020; 10(1): 18481.
- Wilk M, Waśko-Grabowska A, Skoneczna I, et al. Angiotensin system inhibitors may improve outcomes of patients with castration-resistant prostate cancer during abiraterone acetate treatment-a cardio-oncology study. Front Oncol. 2021; 11: 664741.
- Barrett-Lee PJ, Dixon JM, Farrell C, et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol. 2009; 20(5): 816–827.
- Dixon SB, Howell CR, Lu L, et al. Cardiac biomarkers and association with subsequent cardiomyopathy and mortality among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort. Cancer. 2021; 127(3): 458–466.
- Tromp J, Boerman LM, Sama IE, et al. Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls. Eur J Heart Fail. 2020; 22(7): 1239–1246.
- Cao Z, Xu C, Yang H, et al. The role of healthy lifestyle in cancer incidence and temporal transitions to cardiometabolic disease. JACC CardioOncol. 2021; 3(5): 663–674.
- Nolan MT, Marwick TH, Plana JC, et al. Effect of traditional heart failure risk factors on myocardial dysfunction in adult survivors of childhood cancer. JACC Cardiovasc Imaging. 2018; 11(8): 1202–1203.
- Ibanez B, James SK, Ibanez B, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2): 119–177.
- Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021; 42(14): 1289–1367.
- Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with eacts. Eur Heart J. 2018; 39(3): 213–260.
- Saraste A, Knuuti J, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407–477.
- Yun JP, Choi EK, Han KD, et al. Risk of atrial fibrillation according to cancer type: a nationwide population-based study. JACC CardioOncol. 2021; 3(2): 221–232.
- Chen ST, Hellkamp AS, Becker RC, et al. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. Eur Heart J Qual Care Clin Outcomes. 2019; 5(2): 145–152.
- Enriquez A, Biagi J, Redfearn D, et al. Increased incidence of ventricular arrhythmias in patients with advanced cancer and implantable cardioverter-defibrillators. JACC Clin Electrophysiol. 2017; 3(1): 50–56.
- Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Europace. 2022; 24(1): 71–164.
- Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022; 43(40): 3997–4126.
- Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. 2017; 14(12): e503–e551.
- Indik JH, Gimbel JR, Abe H, et al. 2017 HRS expert consensus statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices. Heart Rhythm. 2017; 14(7): e97–e153.
- Tajstra M, Blamek S, Niedziela JT, et al. Patients with cardiac implantable electronic devices undergoing radiotherapy in Poland. Expert opinion of the Heart Rhythm Section of the Polish Cardiac Society and the Polish Society of Radiation Oncology. Kardiol Pol. 2019; 77(11): 1106–1116.
- Zamorano JL, Lancellotti P, Muñoz DR, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines [article in Polish]. Kardiol Pol. 2016; 74(11): 1193–1233.
- Niedziela JT, Blamek S, Gadula-Gacek E, et al. Radiation therapy in patients with cardiac implantable electronic devices. Kardiol Pol. 2021; 79(2): 156–160.
- Puurunen MK, Gona PN, Larson MG, et al. Epidemiology of venous thromboembolism in the Framingham Heart Study. Thromb Res. 2016; 145: 27–33.
- Mulder FI, Carrier M, van Doormaal F, et al. Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data meta-analysis. J Thromb Haemost. 2020; 18(10): 2622–2628.
- Mehta LS, Warnes CA, Bradley E, et al. Cardiovascular considerations in caring for pregnant patients: a scientific statement from the American Heart Association. Circulation. 2020; 141(23): e884–e903.
- Tanous D, Siu SC, Mason J, et al. B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol. 2010; 56(15): 1247–1253.
- Sultan AA, West J, Tata LJ, et al. Risk of first venous thromboembolism in pregnant women in hospital: population based cohort study from England. BMJ. 2013; 347: f6099.
- Hase EA, Barros VI, Igai AM, et al. Risk assessment of venous thromboembolism and thromboprophylaxis in pregnant women hospitalized with cancer: Preliminary results from a risk score. Clinics (Sao Paulo). 2018; 73: e368.
- Tykarski A, Filipiak K, Januszewicz A, et al. 2019 guidelines for the management of hypertension — part 1–7. Arterial Hypertension. 2019; 23(2): 41–87.
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. J Hypertens. 2018; 36(10): 1953–2041.
- Rajzer M, Doroszko A, Filipiak KJ, et al. Nadciśnienie tętnicze w wieku podeszłym — izolowane nadciśnienie skurczowe. Stanowisko Polskiego Towarzystwa Nadciśnienia Tętniczego [article in Polish]. Nadciśnienie Tętnicze w Praktyce. 2022; 8(4): 161–181.
- Doroszko A, Dobrowolski P, Prejbisz A, et al. Nebiwolol i bisoprolol w terapii nadciśnienia tętniczego i chorób towarzyszących — konsensus ekspertów. Nadciśnienie Tętnicze w Praktyce. 2022; 8(1): 1–16.
- Ostrowska A, Prejbisz A, Dobrowolski P, et al. Short and long-term survival in patients hospitalized due to COVID-19 in relation to cardiovascular risk factors and established cardiovascular diseases: the Cor-Cardio Study. Pol Arch Intern Med. 2023: 16441.
- Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022; 43(38): 3618–3731.
- Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012; 125(17): 2128–2137.
- Pietrasik A, Gąsecka A, Kurzyna P, et al. Cancer associated thrombosis: comparison of characteristics, treatment, and outcomes in oncological and non-oncological patients followed by Pulmonary Embolism Response Team. Pol Arch Intern Med. 2023 [Epub ahead of print]: 16421.
- Kurzyna M, Darocha S, Koteja A, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Postepy Kardiol Interwencyjnej. 2015; 11(1): 1–4.
- Darocha S, Kurzyna P, Banaszkiewicz-Cyganik M, et al. An unusual case of CTEPH treated by BPA in a patient with a single lung after cancer surgery. Pulm Circ. 2022; 12(2): e12064.
- Chahine J, Shekhar S, Mahalwar G, et al. Pericardial involvement in cancer. Am J Cardiol. 2021; 145: 151–159.
- Zaha VG, Meijers WC, Moslehi J. Cardio-immuno-oncology. Circulation. 2020; 141(2): 87–89.
- Adler Y, Charron P, Imazio M, et al. et al.. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015; 36(42): 2921–2964.
- Mohamed MO, Van Spall HGC, Kontopantelis E, et al. Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis. Eur Heart J Acute Cardiovasc Care. 2021; 10(8): 829–839.
- Krasiński Z, Urbanek T, Undas A, et al. Guidelines on the prevention and treatment of venous thromboembolism in cancer patients treated surgically, including patients under 18 years of age. Acta Angiol. 2021; 27(3): 81–112.
- Klotzka A, Iwańczyk S, Ropacka-Lesiak M, et al. Anthracycline-induced microcirculation disorders: AIM PILOT Study. Kardiol Pol. 2023 [Epub ahead of print].
- Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018; 36(20): 2017–2023.
- Puślecki M, Stefaniak S, Katarzyński S, et al. AngioVac: The first in Poland percutaneous solid thrombus aspiration from the right atrium. Kardiol Pol. 2022; 80(1): 103–104.
- Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020; 31(2): 171–190.
- Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018; 4(12): 1721–1728.
- Arangalage D, Degrauwe N, Michielin O, et al. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors. Cancer Treat Rev. 2021; 100: 102282.
- Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–3337.
- Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017; 377(9): 829–838.
- Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017; 389(10072): 917–929.
- Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018; 379(21): 2027–2039.
- Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in advanced ALK inhibitor–naive alk-positive non–small cell lung cancer: second interim analysis of the phase III ALTA-1L trial. J Clin Oncol. 2020; 38(31): 3592–3603.
- Solomon BJ, Bauer TM, Mok TSK, et al. First-line lorlatinib or crizotinib in advanced -positive lung cancer. N Engl J Med. 2020; 383(21): 2018–2029.
- Wang L, Wang W. Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non‑small cell lung cancer (Review). Oncol Rep. 2021; 45(1): 13–28.
- Omar NE, Fahmy Soliman AI, Eshra M, et al. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS). ESMO Open. 2021; 6(6): 100315.
- Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018; 378(2): 113–125.
- Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020; 382(1): 41–50.
- Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017; 376(7): 629–640.
- Ewer MS, Tekumalla SH, Walding A, et al. Cardiac safety of osimertinib: a review of data. J Clin Oncol. 2021; 39(4): 328–337.
- Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3): 239–246.
- Sequist LV, Yang JCH, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31(27): 3327–3334.
- Broccoli A, Argnani L, Morigi A, et al. Long-term efficacy and safety of ibrutinib in the treatment of CLL patients: a real life experience. J Clin Med. 2021; 10(24): 5845.
- Treon SP, Meid K, Gustine J, et al. Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with waldenström macroglobulinemia. J Clin Oncol. 2021; 39(6): 565–575.
- Christensen BW, Zaha VG, Awan FT. Cardiotoxicity of BTK inhibitors: ibrutinib and beyond. Expert Rev Hematol. 2022; 15(4): 321–331.
- Sestier M, Hillis C, Fraser G, et al. Bruton's tyrosine kinase inhibitors and cardiotoxicity: more than just atrial fibrillation. Curr Oncol Rep. 2021; 23(10): 113.
- Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37(36): 2768–2801.
- Zangari M, Fink L, Zhan F, et al. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk. 2011; 11(2): 228–236.
- Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011; 29(8): 986–993.
- Giannopoulos K et al. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2021 [text in Polish] 2021.
- Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022; 43(41): 4229–4361.
- Zamorano JL, Lancellotti P, Muñoz DR, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines [article in Polish]. Kardiol Pol. 2016; 74(11): 1193–1233.
- Tajstra M, Blamek S, Niedziela JT, et al. Chorzy z implantowanym urządzeniem do elektroterapii serca poddawani radioterapii w warunkach polskich. Kardiol Pol Zeszyty Edukacyjne. 2019; 77(Suppl. III): 82–89.
